EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of serum amyloid A protein as a biomarker in the diagnosis of 2019 novel coronavirus disease (COVID-19)

Razieh Amini, Mehrdad Mosadegh, Nastaran Ansari, Miaad Banaye Golrizi, Saeed Bashirian, Yousef Erfani, Salman Khazaei, Farid Azizi Jalilian

Microbial Pathogenesis · 2024

DOI: 10.1016/j.micpath.2024.106954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Pathogenesis, 2024. Verfasst von Razieh Amini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Hauptthemen laut MEDLINE: Serum Amyloid A Protein, COVID-19, Biomarkers, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Hamadan University of Medical Sciences, Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The current study aimed to evaluate the prognostic value of serum amyloid A protein)SAA(protein as a biomarker in diagnosing 2019 novel coronavirus disease)COVID-19(infection. METHODS: The study was conducted on 123 patients with definitive COVID-19 infection referred to Shahid Beheshti and Sina hospitals in Hamedan province, Iran. Five-milliliter blood samples were taken from all included patients and serum was isolated using a centrifuge at 10,000 rpm for 10 min. Laboratory tests were conducted, including c-reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR), potassium level, sodium blood test, platelets (PLT), complete blood count (CBC), lymphocyte count, and neutrophil count. The SAA enzyme-linked immunosorbent assay (ELISA) Kit was applied to measure the SAA level in serum samples. RESULTS: 123 patients included 73 males and 50 females, age ±50. Sixty-six (53.7 %) patients had negative CRP while 80 (65 %) patients had normal ESR. Potassium levels were not normal among 111 (94.9 %) patients. Seventy-seven (63.1 %) patients had normal CBC, while 108 (87.8 %) patients had neutrophils above the normal range. 94 (97.9 %) patients over the age of 50 were positive for SAA. In terms of gender, men were the most frequent patients with SAA. There was a statistically significant relationship between the serum level of SAA and outcomes of patients with COVID-19 (p = 0.0001). 94 % of patients with SAA ≤50 were recovered from COVID-19 infection. The sensitivity rate of SAA compared to polymerase chain reaction (PCR) and computed tomography scan (CT scan) tests was 93 % and 99 %, respectively. Moreover, the accuracy of SAA compared to PCR and CT scan tests was 52 % and 96 %, respectively. CONCLUSION: Results indicate the SAA is a sensitive, but not specific biomarker in the early detection of COVID-19. The quantitative levels of SAA can be useful in predicting treatment outcomes among patients with COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serum Amyloid A ProteinCOVID-19BiomarkersSARS-CoV-2HumansMaleFemaleMiddle AgedPrognosisAdultAgedIranBlood SedimentationC-Reactive ProteinSensitivity and SpecificityEnzyme-Linked Immunosorbent AssayYoung Adult

Stichwörter der Autor:innen

2019 novel coronavirus diseaseBiomarkerCT scanPCRSerum amyloid a protein

Substanzen

Serum Amyloid A ProteinBiomarkersC-Reactive Protein

Autor:innen und Institutionen

  • Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Virology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Molecular Virology, Farzan Molecular and Pathobiology Laboratory, Hamadan, Iran.
  • Department of Public Health, School of Health, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.

Förderung

  • Hamadan University of Medical Sciences
  • Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences

Zitieren

APA

Amini, R., Mosadegh, M., Ansari, N., Banaye Golrizi, M., Bashirian, S., Erfani, Y., Khazaei, S., & Azizi Jalilian, F. (2024). Prognostic value of serum amyloid A protein as a biomarker in the diagnosis of 2019 novel coronavirus disease (COVID-19). Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2024.106954

Vancouver

Amini R, Mosadegh M, Ansari N, Banaye Golrizi M, Bashirian S, Erfani Y, et al. Prognostic value of serum amyloid A protein as a biomarker in the diagnosis of 2019 novel coronavirus disease (COVID-19). Microbial Pathogenesis. 2024. doi:10.1016/j.micpath.2024.106954

BibTeX
@article{Amini2024,
  author = {Amini, Razieh and Mosadegh, Mehrdad and Ansari, Nastaran and Banaye Golrizi, Miaad and Bashirian, Saeed and Erfani, Yousef and Khazaei, Salman and Azizi Jalilian, Farid},
  title = {Prognostic value of serum amyloid A protein as a biomarker in the diagnosis of 2019 novel coronavirus disease (COVID-19)},
  journal = {Microbial Pathogenesis},
  year = {2024},
  doi = {10.1016/j.micpath.2024.106954}
}
Kostenlos starten →